Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
New hope for diabetes patients struggling with anxiety and depression
This narrative review examines the relationship between type 2 diabetes and conditions such as anxiety, depression, and cognitive impairment…
Diabetes drugs that control blood sugar might also help improve mood and reduce anxiety for patients living with the condition.
Narrative review examines multidisciplinary strategies for metabolic syndrome in bipolar disorder
Half of Bipolar Patients Face Hidden Heart Risks
This narrative review explores multidisciplinary monitoring and treatment strategies, including lifestyle and pharmacological approaches, fo…
Imagine living with bipolar disorder. You manage your mood swings with medication and therapy.
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use.
Why are so many people getting new diabetes and weight-loss drugs?
This monitoring report analyzes real-world US electronic health record data from Truveta on GLP-1 RA prescribing. It finds increased prescri…
Prescriptions for diabetes and weight-loss drugs jumped sharply in the US after a new oral pill was approved, with first-time use rising ove…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease.
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition. It argues that i…
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
Network meta-analysis finds metabolic surgery superior to GLP-1 agonists for weight loss in obesity
Weight-Loss Surgery Still Leads, But a New Medication Closes the Gap
A network meta-analysis of 20,015 adults with overweight or obesity compared metabolic/bariatric surgery, GLP-1 receptor agonists, and lifes…
Weight-loss surgery still beats drugs overall, but the newest medication tirzepatide closes the gap enough to matter for people who can't ha…
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes.
A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
HFpEF probability scores rule out disease but show limitations in AF and obesity phenotypes.
HFpEF probability scores work well for typical cases but struggle with atrial fibrillation and obesity
This systematic review evaluated the performance of HFpEF probability scores (HFA-PEFF and H2FPEF) in patients with heart failure with prese…
Heart failure scores work well for typical cases but lose accuracy in patients with atrial fibrillation or obesity due to altered biological…
Lixisenatide shows no effect on arterial stiffness in type 2 diabetes with chronic kidney disease
Study finds diabetes drug lixisenatide did not improve artery stiffness in kidney disease patients
A single-center, proof-of-concept randomized controlled trial in 90 people with type 2 diabetes and chronic kidney disease found that 24 wee…
A diabetes drug did not soften arteries in people with kidney disease, showing no improvement in a key heart risk factor after 24 weeks of t…
FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities.
The FDA has approved a new daily pill called FOUNDAYO to help adults manage their weight.
The FDA has approved FOUNDAYO (orforglipron), an oral GLP-1 receptor agonist, for chronic weight management in adults with obesity or overwe…
FDA approves new daily pill FOUNDAYO for adults to manage weight alongside diet and exercise.